Abstract
The efficacy of antifibrinolytics in subarachnoid hemorrhage remains unclear due to conflicting evidence from studies. Online databases were queried to include randomized controlled trials and propensitymatched observational studies. We used Review Manager for the statistical analysis, presenting results as odds ratios with 95% CI. The 12 shortlisted studies included 3359 patients, of which 1550 (46%) were in the intervention (tranexamic acid) group and 1809 (54%) in the control group. Antifibrinolytic therapy significantly reduced the risk of rebleeding (OR: 0.55;95% CI: 0.40-0.75;p=0.0002) with no significant decrease in poor clinical outcome (OR: 1.02;95% CI: 0.86-1.20;p=0.85) and all-cause mortality (OR: 0.92;CI: 0.72-1.17; p=0.50). In patients with subarachnoid hemorrhage, antifibrinolytics reduce the risk of rebleeding without significantly affecting mortality or clinical outcomes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
